We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase

News   Sep 09, 2013

 
Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase
 
 
 

RELATED ARTICLES

5.1 Million Dollar Funding Boost for Blinding Retinal Conditions

News

A $5.1 million grant has been awarded from the California Institute for Regenerative Medicine to advance the development of a novel therapy for blinding retinal conditions.

READ MORE

Drug Could Sustain Oxygen-Starved Hearts

News

In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.

READ MORE

Functioning 3D Human Neural Networks Developed From Stem Cells

News

This 3D neuro-model could help uncover early stage biomarkers of disease, in turn supporting earlier diagnosis and improving understanding of disease progression.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE